Regulatory Matters to this Form 10-K. In connection with our ongoing development activities, we currently depend, and expect to continue to depend, on numerous third parties, including contract research organizations, clinical trial investigators and contract manufacturing organizations. If any of these service providers breach or terminate its agreement with us or otherwise fail to conduct the service for which it is responsible successfully and in a timely and compliant manner, the development...
Q2 FY2026 — expected 2026-08-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073498 | EDGAR | 107K words |
| 2025-02-26 | 2024-12-31 | 0001628280-25-007970 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0001628280-24-006158 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001628280-23-004698 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001628280-22-003657 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001628280-21-003336 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001628280-20-002197 | EDGAR | — |
| 2019-02-20 | 2018-12-31 | 0001628280-19-001574 | EDGAR | — |
| 2018-02-26 | 2017-12-31 | 0001628280-18-002261 | EDGAR | — |
| 2017-02-23 | 2016-12-31 | 0001193125-17-053986 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268113 | EDGAR | 45K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103544 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001628280-25-022872 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001628280-24-045459 | EDGAR | — |
| 2024-07-31 | 2024-06-30 | 0001628280-24-033630 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001628280-24-019798 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001628280-23-036214 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001628280-23-027015 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015464 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-027986 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020872 | EDGAR | — |
| 2022-04-29 | 2022-03-31 | 0001628280-22-011291 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001193125-26-073439 | EDGAR | 6K words |
| 2025-11-12 | 0001193125-25-277754 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268103 | EDGAR | — |
| 2025-08-11 | 0001193125-25-178046 | EDGAR | — |
| 2025-08-06 | 0000950170-25-103543 | EDGAR | — |
| 2025-07-22 | 0001193125-25-162233 | EDGAR | — |
| 2025-05-07 | 0001628280-25-022871 | EDGAR | — |
| 2025-05-05 | 0001193125-25-112812 | EDGAR | — |
| 2025-04-01 | 0001193125-25-069927 | EDGAR | — |
| 2025-02-26 | 0001628280-25-007965 | EDGAR | — |
204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001521036 |
| Ticker | LNTH |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.lantheus.com |
| Listed | 2015-06-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report